Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis.
The natural history of primary progressive MS in British Columbia, Canada.
Episode 41 with Dr. Diego Cadavid on a clinical trial of anti-LINGO-1
Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.
Episode 45 with Dr. Simon Hametner on the role of iron in MS
Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair
MS Research Roundup: January 29, 2014
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
EMD Serono Joins ACP to Launch OPT-UP Study
Demyelination of the hippocampus is prominent in the cuprizone model.
Invitation to Share Your Thoughts on a New MS Research Resource
Neuroprotective effects of testosterone treatment in men with multiple sclerosis.
Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report.
Teriflunomide added to interferon-β in relapsing multiple sclerosis: A randomized phase II trial.
MS Research Roundup: January 31, 2014
Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Transfer of interferon β-1a into human breastmilk.
IL-17 and Th17 Cells.
Neuroprotection mediated through estrogen receptor-alpha in astrocytes.
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Gender and the hygiene hypothesis.

Pages